Amgen, Inc.’s newly-approved interchangeable biosimilar to Johnson & Johnson’s anti-inflammatory drug Stelara will face challenges in generating solid returns in the Medicare Part D program because the innovator's price could be substantially reduced by the government in 2026, one year after the biosimilar’s expected January 2025 launch.
Amgen Biosimilar For Stelara May Face Price Drop In Medicare Shortly After Launch; What’s A Follow-On To Do?
With J&J's Stelara set for Medicare negotiation, the fate of Amgen’s new ustekinumab interchangeable be a test case for concerns that the pricing program will significantly undercut incentives for developing biosimilars for blockbusters in the Medicare market.
